Positive AGM Statement
RUA Life Sciences’ AGM statement led with an update on its two revenue-generating businesses for the first four months of FY 2023. This leaves us room to upgrade our FY revenue forecasts, but for the moment we have kept them unchanged, and our valuation remains at £121.0m or 545p per share. Progress on RUA’s vascular and heart valve products continues and a clinical trial update on the former is expected in late September. All resolutions were passed at the RUA Life Sciences AGM.Revenues from RUA’s two cash-generative businesses – biomaterials and contract manufacturing – were 73% and 44% ahead, respectively, on the same four-month period last year. Together, this puts RUA on a full-year total revenue run-rate that is just over 16% above our forecasts.
RUA appears to be working well with the FDA on aligning and agreeing the size, endpoints and statistical analysis plan for the small clinical trial needed for 510(k) approval of their large-bore vascular graft product.
Aortech International is an Intellectual Property (IP) holding company whose principal activity is exploiting the value of its IP and know-how.
Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.